Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sequential designs for logistic phase I clinical trials.

Guohui Liu1, William F Rosenberger, Linda M Haines

  • 1Department of Mathematics and Statistics, University of Maryland, Baltimore, USA. Guohui.Liu@mpi.com

Journal of Biopharmaceutical Statistics
|October 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A bilayer polyurethane scaffold integrating degradation-dependent therapeutic release with directional exudate transport for diabetic wound healing.

Biomaterials advances·2026
Same author

Anxiety and depression among survivors 5 years after the Lushan earthquake: a large cross-sectional clinical diagnostic study.

BMC psychiatry·2026
Same author

A Case Report of Familial Primary Hyperoxaluria Type 1 Nephropathy with c.781C>G Gene Mutation and Literature Review.

Annals of clinical and laboratory science·2026
Same author

PIWIL3-piRNA pathway controls rabbit oogenesis and embryogenesis via broad regulation of the transcriptome and proteome.

Nature communications·2026
Same author

All-in-one: a CGRP-encapsulated Rh-GelMA supramolecular dual-network hydrogel orchestrating immune-vascular coupling for diabetic wound healing.

Journal of nanobiotechnology·2026
Same author

Newly Emerging Nanotechnologies of Innovative Devices for Radioisotope Batteries.

Nanomaterials (Basel, Switzerland)·2026
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

This study introduces a systematic approach for phase I clinical trials to efficiently estimate the maximum tolerated dose using logistic models. It addresses challenges with maximum likelihood estimates and incorporates ethical dose limits.

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Pharmacology

Background:

  • Phase I clinical trials commonly employ parametric and nonparametric sequential designs for dose escalation.
  • Estimating the maximum tolerated dose (MTD) is crucial for patient safety and treatment efficacy.
  • Existing methods may face challenges with parameter estimation and ethical dose constraints.

Purpose of the Study:

  • To develop and evaluate a systematic, efficient approach for estimating the maximum tolerated dose (MTD) in phase I clinical trials.
  • To address the nonexistence of maximum likelihood estimates (MLEs) for logistic parameters in dose-finding studies.
  • To integrate ethical considerations, such as maximum acceptable dose limits, into sequential trial designs.

Main Methods:

  • A systematic approach combining start-up, follow-on, and sequential dose-finding designs with an estimation method.

Related Experiment Videos

  • Incorporation of a constraint on the probability of an undetermined maximum likelihood estimator (MLE) for logistic parameters.
  • Simulation studies comparing the proposed systematic designs with nonparametric designs in both continuous and discrete dose spaces.

    • Main Results:

    • The systematic approach provides an efficient estimation of the MTD under a logistic dose-response model.
    • The proposed method effectively handles issues related to the nonexistence of MLEs.
    • The approach demonstrates flexibility in incorporating ethical dose constraints, enhancing patient safety.

    Conclusions:

    • The developed systematic sequential design offers an efficient and robust method for MTD estimation in phase I clinical trials.
    • This approach improves upon existing methods by addressing parameter estimation challenges and ethical considerations.
    • The findings support the use of this systematic design for optimizing dose-finding studies.